| Haylee Thompson, FNP | |
|
221 5th Ave S, Glasgow, MT 59230-2600 | |
| (406) 228-3400 | |
| (406) 228-3413 |
| Full Name | Haylee Thompson |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 11 Years |
| Location | 221 5th Ave S, Glasgow, Montana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205224060 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 44999 (Montana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Frances Mahon Deaconess Hospital | Glasgow, MT | Hospital |
| Trinity Hospital | Wolf point, MT | Hospital |
| Billings Clinic | Billings, MT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Frances Mahon Deaconess Hospital | 3173430949 | 35 |
News Archive
Researchers in the United States have conducted a study demonstrating the potential of a novel therapeutic approach to treating coronavirus disease 2019 (COVID-19). The therapy augments the body's T cell response to the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by providing a boost of rapidly expanded virus-specific T cells.
The ALS Therapy Development Institute and Oxford BioMedica announced today the extension of their collaboration following successful completion of the first phase. The extended collaboration, which is funded by the Muscular Dystrophy Association, aims to advance the development of Oxford BioMedica's preclinical gene therapy candidate, MoNuDin®, and to evaluate other gene-based strategies for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).
Patients electing cosmetic facial procedures such as rhinoplasty at St. Louis Cosmetic Surgery may be less likely to suffer complications, thanks to the way doctors at the practice have responded to a new study.
Lung cancer is a major global cause of mortality, reportedly accounting for 1.7 million deaths each year. The most common form of lung cancer is non-small-cell lung cancer (NSCLC), and early-stage NSCLCs can often be surgically resected.
› Verified 1 days ago
| Entity Name | Frances Mahon Deaconess Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639117013 PECOS PAC ID: 3173430949 Enrollment ID: O20031111000918 |
News Archive
Researchers in the United States have conducted a study demonstrating the potential of a novel therapeutic approach to treating coronavirus disease 2019 (COVID-19). The therapy augments the body's T cell response to the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by providing a boost of rapidly expanded virus-specific T cells.
The ALS Therapy Development Institute and Oxford BioMedica announced today the extension of their collaboration following successful completion of the first phase. The extended collaboration, which is funded by the Muscular Dystrophy Association, aims to advance the development of Oxford BioMedica's preclinical gene therapy candidate, MoNuDin®, and to evaluate other gene-based strategies for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).
Patients electing cosmetic facial procedures such as rhinoplasty at St. Louis Cosmetic Surgery may be less likely to suffer complications, thanks to the way doctors at the practice have responded to a new study.
Lung cancer is a major global cause of mortality, reportedly accounting for 1.7 million deaths each year. The most common form of lung cancer is non-small-cell lung cancer (NSCLC), and early-stage NSCLCs can often be surgically resected.
› Verified 1 days ago
| Entity Name | Riverside Family Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255351862 PECOS PAC ID: 7810989506 Enrollment ID: O20040401001068 |
News Archive
Researchers in the United States have conducted a study demonstrating the potential of a novel therapeutic approach to treating coronavirus disease 2019 (COVID-19). The therapy augments the body's T cell response to the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by providing a boost of rapidly expanded virus-specific T cells.
The ALS Therapy Development Institute and Oxford BioMedica announced today the extension of their collaboration following successful completion of the first phase. The extended collaboration, which is funded by the Muscular Dystrophy Association, aims to advance the development of Oxford BioMedica's preclinical gene therapy candidate, MoNuDin®, and to evaluate other gene-based strategies for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).
Patients electing cosmetic facial procedures such as rhinoplasty at St. Louis Cosmetic Surgery may be less likely to suffer complications, thanks to the way doctors at the practice have responded to a new study.
Lung cancer is a major global cause of mortality, reportedly accounting for 1.7 million deaths each year. The most common form of lung cancer is non-small-cell lung cancer (NSCLC), and early-stage NSCLCs can often be surgically resected.
› Verified 1 days ago
| Entity Name | Wolf Point Clinic Association Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992722904 PECOS PAC ID: 3678546660 Enrollment ID: O20040817001372 |
News Archive
Researchers in the United States have conducted a study demonstrating the potential of a novel therapeutic approach to treating coronavirus disease 2019 (COVID-19). The therapy augments the body's T cell response to the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by providing a boost of rapidly expanded virus-specific T cells.
The ALS Therapy Development Institute and Oxford BioMedica announced today the extension of their collaboration following successful completion of the first phase. The extended collaboration, which is funded by the Muscular Dystrophy Association, aims to advance the development of Oxford BioMedica's preclinical gene therapy candidate, MoNuDin®, and to evaluate other gene-based strategies for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).
Patients electing cosmetic facial procedures such as rhinoplasty at St. Louis Cosmetic Surgery may be less likely to suffer complications, thanks to the way doctors at the practice have responded to a new study.
Lung cancer is a major global cause of mortality, reportedly accounting for 1.7 million deaths each year. The most common form of lung cancer is non-small-cell lung cancer (NSCLC), and early-stage NSCLCs can often be surgically resected.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Haylee Thompson, FNP 1128 1st Ave N, Glasgow, MT 59230-2257 Ph: (406) 480-5918 | Haylee Thompson, FNP 221 5th Ave S, Glasgow, MT 59230-2600 Ph: (406) 228-3400 |
News Archive
Researchers in the United States have conducted a study demonstrating the potential of a novel therapeutic approach to treating coronavirus disease 2019 (COVID-19). The therapy augments the body's T cell response to the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by providing a boost of rapidly expanded virus-specific T cells.
The ALS Therapy Development Institute and Oxford BioMedica announced today the extension of their collaboration following successful completion of the first phase. The extended collaboration, which is funded by the Muscular Dystrophy Association, aims to advance the development of Oxford BioMedica's preclinical gene therapy candidate, MoNuDin®, and to evaluate other gene-based strategies for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).
Patients electing cosmetic facial procedures such as rhinoplasty at St. Louis Cosmetic Surgery may be less likely to suffer complications, thanks to the way doctors at the practice have responded to a new study.
Lung cancer is a major global cause of mortality, reportedly accounting for 1.7 million deaths each year. The most common form of lung cancer is non-small-cell lung cancer (NSCLC), and early-stage NSCLCs can often be surgically resected.
› Verified 1 days ago
Dr. Brandi Lynn Knierim, DNP, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 24 Newton Ave, Glasgow, MT 59230 Phone: 406-263-8444 | |
Dr. Dawn Ranae Sugg, CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 238 2nd Ave S, Glasgow, MT 59230 Phone: 406-868-8177 | |
Christina Hartshorn, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 221 5th Ave S, Glasgow, MT 59230 Phone: 406-228-3400 Fax: 406-228-3413 | |
Desiree Cavan, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 221 5th Ave S, Glasgow, MT 59230 Phone: 406-228-3400 | |
Michele Beebe, MSN, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 630 2nd St. So., Ste. A, Glasgow, MT 59230 Phone: 406-228-4101 Fax: 406-228-4101 | |
Kristi Toennis, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 221 5th Ave S, Glasgow, MT 59230 Phone: 406-228-3400 Fax: 406-228-3413 |